These data point toward a fork recovery mechanism that relies on RNF168-mediated recruitment of RAD18 to stalled replication forks in BRCA1-deficient cancer cells treated with HU, along with UBC13, PCNA ubiquitination, and PALB2. Here, RNF168 is linked to cancer.